Ra Capital Management, L.P. Acquires 6,552 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 6,552 shares of the stock in a transaction dated Monday, July 13th. The shares were bought at an average price of $8.94 per share, for a total transaction of $58,574.88. Following the completion of the acquisition, the director owned 16,817,573 shares in the company, valued at $150,349,102.62. This represents a 0.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.97 per share, with a total value of $135,464.94.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. acquired 31,000 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.57 per share, for a total transaction of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $9.92 on Thursday. The stock’s 50 day moving average price is $8.96 and its 200 day moving average price is $7.06. Artiva Biotherapeutics, Inc. has a 52 week low of $2.07 and a 52 week high of $14.53. The company has a market capitalization of $245.22 million, a P/E ratio of -2.80 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Wedbush boosted their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ARTV. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $41,000. Bank of America Corp DE lifted its position in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Artiva Biotherapeutics during the 1st quarter valued at approximately $131,000. OMERS ADMINISTRATION Corp bought a new stake in Artiva Biotherapeutics during the 4th quarter valued at approximately $91,000. Finally, Sanctuary Advisors LLC bought a new stake in Artiva Biotherapeutics during the 1st quarter valued at approximately $139,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.